Akari Therapeutics Plc - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Akari Therapeutics Plc covers the period from August 16, 2016, to September 6, 2016. The report discloses a specific transaction involving a company director rather than providing comprehensive financial results for a fiscal period.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to a specific insider transaction:
- Insider Purchase: Mark Cohen, Director and Vice Chairman.
- Shares Purchased: 4,981 American Depositary Shares (representing 498,100 ordinary shares).
- Price Range: $9.22 to $10.9728 per share.
- Total Cost: $49,305.10.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing solely reports the aforementioned insider purchase activity.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the current share price relative to the $9.22–$10.97 range paid by the director in September 2016.
- Confirm if this purchase was part of a pre-arranged trading plan (Rule 10b5-1) or a discretionary decision.
- Check subsequent filings for any additional insider trading activity by Mark Cohen or other executives.